Savolitinib

Generic Name: Savolitinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₅N_₉

CAS Number: 1313725-88-0

Unique Ingredient Identifier: 2A2DA6857R

Background: Savolitinib has been used in trials studying the treatment and health services research of Tumor, Food Effect, Gastric Cancer, Health Subjects, and Colorectal Cancer, among others.

Indication: 用于含铂化疗后疾病进展或不耐受标准含铂化疗的、具有间质-上皮转化因子（MET）外显子14跳变的局部晚期或转移性非小细胞肺癌成人患者。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer

Phase 1

Completed

Conditions: Gastric Cancer

Interventions: Drug: Volitinib
Drug: Docetaxel

First Posted Date: 2014-09-30

Last Posted Date: 2016-04-08

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 25

Registration Number: NCT02252913

Locations: 🇨🇳
Fudan University Shanghai Cancer Hospital, Shanghai, China

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer Metastatic

Interventions: Drug: AZD2014
Drug: Standard maintenance for squamous NSCLC
Drug: Durvalumab
Drug: AZD4547
Drug: Pemetrexed
Drug: AZD5363
Drug: AZD8931
Drug: Selumetinib
Drug: Vandetanib
Drug: savolitinib
Drug: Olaparib

First Posted Date: 2014-04-17

Last Posted Date: 2024-01-10

Lead Sponsor: UNICANCER

Target Recruit Count: 999

Registration Number: NCT02117167

Locations: 🇫🇷
Hôpital Avicenne, Bobigny, France
🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷
Institut Paoli Calmettes, Marseille, France

and more 34 locations

A Food Effect Phase I Study of the Volitinib in Healthy Subjects

Phase 1

Completed

Conditions: Food Effect
Health Subjects

Interventions: Drug: Volitinib

First Posted Date: 2013-12-20

Last Posted Date: 2019-05-14

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 25

Registration Number: NCT02017236

Locations: 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China

Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Tumor

Interventions: Drug: Volitinib

First Posted Date: 2013-01-21

Last Posted Date: 2016-06-01

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 47

Registration Number: NCT01773018

Locations: 🇦🇺
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
🇦🇺
Austin Health, Melbourne, Australia
🇦🇺
Southern Health and Monash Institute of Medical Research, Clayton, Australia

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy